XTL Biopharmaceuticals - ADR Peer Comparison
$2.53
$0.03
(1.20%)
As on 04-Sep-2026 13:21EDT
Market cap
$6 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Edit
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6 | 2,928 | 2,262 | 2,152 | 1,862 |
Revenue ($ Mln) |
-- | 450 | 120 | 549 | 1,044 |
Net Profit ($ Mln) |
-6.97 | -188.21 | -57.50 | 17.88 | 488.78 |
Net Margin (%) |
-238.78 | -41.86 | -144.33 | 3.26 | 46.83 |
RoE (%) |
-269.02 | -28.46 | -9.86 | 1.43 | 15.95 |
Price to Earnings |
-- | -- | -- | 123.80 | 3.18 |
Price-To-Book |
1.90 | 4.96 | 4.15 | 1.71 | 0.49 |
Income Statement ($ Mln)
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 460.16 | 17.20 | 549.96 | 1,112.25 |
|
Cost of Revenue
|
0.00 | 191.08 | 5.13 | 337.24 | 29.74 |
|
Gross Profit
|
0.00 | 269.08 | 12.07 | 212.72 | 1,082.51 |
|
Operating Expenses
|
1.69 | 492.65 | 74.51 | 267.45 | 581.12 |
|
Operating Profit (EBIT)
|
-1.69 | -223.57 | -62.44 | -54.73 | 501.39 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-0.76 | -178.46 | -101.81 | 522.72 | 300.87 |
|
Provision for Tax
|
-- | -2.93 | 0.33 | 63.78 | -18.62 |
|
Profit after Tax (Net Income)
|
-6.97 | -175.54 | -102.14 | 458.12 | 320.88 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-0.25 | 715.50 | 597.44 | 1,237.93 | 3,234.49 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 40.72 | 84.62 | 186.06 | 17.78 |
|
Current Liabilities
|
0.42 | 416.17 | 102.63 | 315.78 | 152.80 |
|
Total Liabilities
|
0.17 | 1,172.38 | 784.68 | 1,753.10 | 3,405.07 |
Assets ($ Mln)
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 153.10 | 580.33 | 185.76 | 326.92 |
|
Current Assets
|
0.17 | 1,019.29 | 204.35 | 1,567.35 | 3,078.15 |
|
Total Assets
|
0.17 | 1,172.38 | 784.68 | 1,753.10 | 3,405.07 |
|
Total Debt*
|
0.27 | 224.26 | 128.16 | 97.89 | 6.92 |
|
Net Current Assets
|
-0.25 | 603.12 | 101.72 | 1,251.57 | 2,926.59 |
Cashflow ($ Mln)
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.03 | -150.79 | -49.95 | -64.66 | -189.23 |
|
Cash Flow from Investing Activities
|
0.52 | 307.87 | 0.12 | -29.41 | 219.35 |
|
Cash from Financing Activities
|
0.21 | 72.35 | 147.34 | 7.84 | -3.14 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-249.43 | -18.15 | -15.42 | 41.92 | 10.44 |
|
ROE (%)
|
-269.02 | -22.56 | -18.95 | 45.86 | 10.47 |
|
ROA (%)
|
-159.91 | -14.89 | -14.05 | 30.27 | 8.51 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -38.15 | -593.92 | 83.30 | 28.85 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-1.00 | 0.15 | 1.91 | -0.13 | 3.04 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-578.58 | 31.73 | -16.13 | 1,114.23 | 333.15 |
|
EPS Growth (%)
|
-13,591.31 | 0.37 | -0.02 | 11.14 | 3.39 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.04 | -11.11 | -13.58 | 5.08 | 6.71 |
|
Price / Book Value
|
-1.00 | 2.73 | 2.32 | 1.88 | 0.67 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.51 | -9.39 | -18.38 | -25.58 | -2.33 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.06 | 0.31 | 0.21 | 0.08 | 0.00 |
|
Short term debt to equity ratio
|
-1.06 | 0.29 | 0.10 | 0.02 | 0.00 |
|
Current Ratio
|
0.40 | 2.45 | 1.99 | 4.96 | 20.15 |
|
Quick Ratio
|
-- | 2.27 | 1.77 | 4.83 | 20.00 |
|
Interest Coverage
|
-- | -33.26 | -3.49 | -19.05 | 136.71 |
Operating Efficiency Ratios
| XTL Biopharmaceuticals - ADR | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Galapagos NV - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 23.06 | 86.44 | 26.88 | 4.78 |
|
Asset Turnover
|
0.00 | 0.39 | 0.02 | 0.36 | 0.29 |
|
Receivable days
|
-- | 77.60 | 380.35 | 104.79 | 16.53 |
|
Inventory Days
|
-- | 109.55 | 791.94 | 49.57 | 452.54 |
|
Payable days
|
-- | 231.78 | 931.00 | 47.68 | 1,242.94 |
|
Cash Conversion Cycle
|
-- | -44.63 | 241.30 | 106.67 | -773.87 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
